Justyna Siwy
As seen in:
Nature,
Wiley Online Library,
PLOS ONE,
heart,
MDPI,
Nephrology Dialysis Transplantation,
medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Justyna Siwy
Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases
Abstract Background: Fibrosis, characterised by excessive accumulation of collagen type I (COL1), is a common feature of chronic diseases, including liver diseases (LDs), chronic kidney disease (CKD) and heart failure (HF). COL1 degradation products can be detected in urine by proteomics/ peptidomics analyses and may serve as non-invasive biomarkers of fibrosis.
Urinary Peptidomic Profiling In Post‐Acute Sequelae of SARS‐CoV‐2 Infection: A Case‐Control Study
A1AT Alpha-1-antitrypsin APOA2 Apolipoprotein A-II APOA4 Apolipoprotein A-IV ARB Angiotensin II receptor blockers AT III Antithrombin-III AUC Area under the curve B2M Beta-2-microglobulin CALR Calreticulin CCC Canadian Consensus Criteria CE-MS Capillary-electrophoresis-mass-spectrometry CI Confidence intervals CLCB Clathrin CO1A1 Collagen alpha-1(I) CO1A2 Collagen alpha-2(I) CO3A1 Collagen alpha-1(III) CO4A2 Collagen alpha-2(IV) COEA1 Collagen alpha-1(XIV) COVID-19 Coronavirus disease 2019...
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Abstract Objective Heart failure (HF) is characterised by collagen deposition. Urinary proteomic profiling (UPP) followed by peptide sequencing identifies parental proteins, for over 70% derived from collagens. This study aimed to refine understanding of the antifibrotic action of spironolactone. Methods In this substudy (n=290) to the Heart ‘Omics’ in Ageing Study trial, patients were randomised to usual therapy combined or not with spironolactone 25–50 mg/day and followed for 9 months.
Mortality Risk and Urinary Proteome Changes in Acute COVID-19 Survivors in the Multinational CRIT-COV-U Study
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Mortality Risk and Urinary Proteome Changes of Acute COVID-19 Survivors in the Multinational Study CRIT-COV-U Study
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 19 August 2024 / Approved: 19 August 2024 / Online: 19 August 2024 (13:58:06 CEST) Siwy, J.; Keller, F.; Banasik, M.; Peters, B.; Dudoignon, E.; Mebazaa, A.; Gülmez, D.; Spasovski, G.; Lazo, M. S.; Rajzer, M.; Fuławka, Ł.; Dzitkowska-Zabielska, M.; Mischak, H.; Hecking, M.; Beige, J.; Wendt, R. Mortality Risk and Urinary Proteome Changes of Acute COVID-19 Survivors in the Multinational Study CRIT-COV-U Study.
Mortality risk in survivors of acute COVID-19 and the urinary proteome: Follow-up results from a multinational study that prospectively evaluated a proteomic urine test for early and accurate prognosis of critical course complications in patients with SAR
H.M. the co-founder and co-owner of Mosaiques Diagnostics. J.S. is employed by Mosaiques-Diagnostics GmbH.
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Discussion This preplanned substudy to the randomised controlled HOMAGE-RCT trial, to our knowledge for the first time assessed UPP changes in response to spironolactone in patients at high HF risk because of coronary heart disease. The following key observations summarise the results.
Small peptide CSF fingerprint of amyotrophic lateral sclerosis
Discussion The objective of this open rapid publication is stimulation of further research regarding the peptides and parental proteins which we found to be differentially regulated in a population of 50 ALS patients compared to peptides in non-ALS individuals. It is important to understand that the identification of peptides in our study was performed without previous protease digestion in a preparatory one-pot approach and holistically (capturing all peptides up to 20 kDa molecular mass) [13].
Integration of Urinary Peptidome and Fecal Microbiome to Explore Patient Clustering in Chronic Kidney Disease
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Multiple urinary peptides display distinct sex‐specific distribution
AKAP12 A-kinase anchor protein 12 BMI body mass index CD99 CD99 antigen CE-MS capillary electrophoresis-coupled to mass spectrometry COL1A1 collagen alpha-1(I) chain COL1A2 collagen alpha-2(I) chain COL2A1 collagen alpha-1(II) chain COL3A1 collagen alpha-1(III) chain COL4A3 collagen alpha-3(IV) chain COL5A2 collagen alpha-2(V) chain COL6A1 collagen alpha-1(VI) chain COL9A2 collagen alpha-2(IX) chain eGFR estimated glomerular filtration rate GTEx Genotype-Tissue Expression HBA hemoglobin...
IJMS | Free Full-Text | Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways following GLP-1R Agonist Treatment
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Urine Peptidome Analysis Identifies Common and Stage-Specific Markers in Early Versus Advanced CKD
1. Introduction Chronic kidney disease (CKD) is defined as persistent (over 3 months) structural or functional aberrations to renal tissue, detrimental for health [1]. Structural abnormalities include structures, such as polycystic kidneys, while abnormal kidney function is expressed as glomerular filtration rate < 60 mL/min/1.73 m2, albuminuria ≥ 30 mg/24 h or ACR ≥ 30 mg/g.
Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors
Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-23585-y, published online 27 March 2018 The Author Contributions section in this Article is incorrect. “I.B., M.F. and A.L. wrote the main manuscript text. I.B., M.F., A.L., J.S. and J.M. analyzed the peptidomics data and performed the statistical analysis. V.J., A.V., J.S., J.M., A.S.M. and H.M. contributed to the writing of the manuscript. I.B. prepared all figures, tables and supplementary materials.
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis
Background In spite of its invasive nature and risks, kidney biopsy is currently required for precise diagnosis of many chronic kidney diseases (CKDs). Here, we explored the hypothesis that analysis of the urinary proteome can discriminate different types of CKD irrespective of the underlying mechanism of disease. Methods We used data from the proteome analyses of 1180 urine samples from patients with different types of CKD, generated by capillary electrophoresis coupled to mass spectrometry.
Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression
Background Autosomal dominant polycystic kidney disease (ADPKD) is characterized by slowly progressive bilateral renal cyst growth ultimately resulting in loss of kidney function and end-stage renal disease (ESRD). Disease progression rate and age at ESRD are highly variable. Therapeutic interventions therefore require early risk stratification of patients and monitoring of disease progression in response to treatment.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Justyna
Contact Justyna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack